Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-11-10 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the repurchase of its own shares over a specific period (November 3 to November 7, 2025). It includes detailed tables of daily aggregated volumes and individual transaction logs, which is characteristic of a 'Transaction in Own Shares' (POS) filing, often required under market abuse regulations (MAR).
2025-11-10 English
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing positive Phase 3 clinical trial results for their drug 'Dupixent' in treating allergic fungal rhinosinusitis (AFRS). It details clinical trial data, regulatory status (FDA priority review), and provides background information on the companies. This type of document is a standard corporate announcement regarding product development and regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into specific financial reporting categories like 10-K, IR, or ER.
2025-11-07 French
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA prior
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing positive Phase 3 clinical trial results for their drug 'Dupixent' and the acceptance of an sBLA by the FDA. This type of corporate communication, which details product development, clinical trial outcomes, and regulatory status, is classified as a general regulatory announcement or corporate update. Since it does not fit into specific categories like financial reports, earnings releases, or shareholder meeting materials, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2025-11-07 English
Regulatory Filings 2025
Regulatory Filings
2025-11-04 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a 'Déclaration des transactions sur actions propres' (Declaration of transactions in own shares) from Sanofi. It provides a detailed breakdown of share buyback transactions conducted over a specific period (October 27 to October 31, 2025), including daily aggregated volumes and individual transaction details. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-11-03 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (27 October 2025 to 31 October 2025). It includes tables detailing daily volumes, weighted average prices, and individual transaction logs. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-11-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.